SCHEMBL23779696

SCHEMBL23779696

C[Si](C)(C)N(CCCOCCOCCOCCCN([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C

nearest known ligand 0.30

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.30
THRB P10828 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23779694 1.00 MEN1 (0.30) MEN1THRBHTTKMT2AMAPT
SCHEMBL23779695 1.00 MEN1 (0.30) MEN1THRBHTTKMT2AMAPT
SCHEMBL23779690 1.00 MEN1 (0.30) MEN1THRBHTTKMT2AMAPT
SCHEMBL23779689 0.95
SCHEMBL23779683 0.95
SCHEMBL23779686 0.95
SCHEMBL23779681 0.95
SCHEMBL23779682 0.95 MEN1 (0.30) MEN1THRBHTTKMT2AMAPT
SCHEMBL23779680 0.90
SCHEMBL23779691 0.84 MEN1 (0.30) MEN1THRBHTTKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12091491-B2 Silylamine compound and latent curing agent comprising said silylamine compound KOEI CHEMICAL COMPANY, LIMITED (JP) 2024-09-17 US disclosed
US-20220119583-A1 SILYLAMINE COMPOUND AND LATENT CURING AGENT COMPRISING SAID SILYLAMINE COMPOUND KOEI CHEMICAL COMPANY, LIMITED (JP) 2022-04-21 US disclosed
EP-3875461-A1 SILYLAMINE COMPOUND AND LATENT CURING AGENT COMPRISING SAID SILYLAMINE COMPOUND Koei Chemical Company, Limited (JP) 2021-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119583-A1 SILYLAMINE COMPOUND AND LATENT CURING AGENT COMPRISING SAID SILYLAMINE COMPOUND CDKN1A, SIRT2, H1-4 MEN1 2165/4885THRB 4582/4885HTT 4234/4885
US-12091491-B2 Silylamine compound and latent curing agent comprising said silylamine compound CDKN1A, SIRT2, H1-4 MEN1 2165/4885THRB 4582/4885HTT 4234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.